The Implication of Mechanistic Approaches and the Role of the Microbiome in Polycystic Ovary Syndrome: A Review

    January 2023 in “ Metabolites ”
    Anirban Goutam Mukherjee, Uddesh Ramesh Wanjari, Sandra Kannampuzha, Reshma Murali, Arunraj Namachivayam, Raja Ganesan, Abhijit Dey, Achsha Babu, Kaviyarasi Renu, Balachandar Vellingiri, Gnanasambandan Ramanathan, George Priya Doss C, Nehal M. Elsherbiny, Amira M. Elsherbini, Alsamman M. Alsamman, Hatem Zayed, Abilash Valsala Gopalakrishnan
    Image of study
    TLDR Changes in gut bacteria can contribute to the development of Polycystic Ovary Syndrome (PCOS), affecting metabolism, immunity, and causing inflammation. Treatments may involve adjusting these factors.
    Polycystic Ovary Syndrome (PCOS) is a complex condition affecting women's reproductive health, with symptoms such as hirsutism, hyperandrogenism, ovulatory dysfunction, irregular menstruation, and infertility. The review suggests that alterations in the gut microbiome play a significant role in the development of PCOS, affecting metabolic and immunological function, and causing inflammation. PCOS patients show changes in gut microbiota, with a higher prevalence of certain bacterial species and lower levels of beneficial bacteria. These changes can lead to systemic low-grade inflammation, insulin resistance, and affect sex hormone changes. The review also highlights the role of metabolites such as bile acids, short-chain fatty acids (SCFAs), ceramides, and trimethylamine N-oxide (TMAO) in the development of PCOS. Potential treatments for PCOS may include modulating these factors, such as administering exogenous IL-22 and altering the gut microbiome. However, more research is needed to fully understand these mechanisms and their implications for treatment.
    Discuss this study in the Community →

    Research cited in this study

    20 / 20 results

    Related Community Posts Join

    6 / 27 results

      community Dutasteride is amazing even for women with FAGA!

      in Female  151 upvotes 3 months ago
      Dutasteride significantly improved hair health and reduced shedding for a woman with PCOS and hyperandrogenism, without causing depression or anxiety, unlike finasteride. Dutasteride also helped with PMDD symptoms and had no side effects, though it changed hair texture.

      community DHT levels after 4 weeks of Fina and 8 weeks of Fina + 4 weeks of Duta

      in Update  35 upvotes 6 years ago
      The user reported early stage diffuse hair thinning and increased DHT levels after 4 weeks on Finasteride and 8 weeks on Finasteride plus 4 weeks on Dutasteride, despite the medications being authentic and stored properly. They are considering increasing their Dutasteride dosage due to the lack of side effects and are unsure if the treatment is helping their hair.

      community AA and Hirsutism but T levels are normal

      in Female  6 upvotes 4 years ago
      27-year-old female experiences aggressive hair thinning and hirsutism despite normal testosterone levels. Spironolactone and 2% minoxidil were ineffective; high DHEA sulfate levels may be the cause.

      community Finasteride 5mg & Spironolactone 100mg

      in Female  2 upvotes 1 year ago
      A 20-year-old female is using finasteride 5mg and spironolactone 100mg for severe hirsutism and is experiencing minor side effects like water weight loss and irregular periods. She is concerned about potential future side effects and hair regrowth on her scalp.

      community No, Finasteride as a treatment for MPB was not an "accident"

      in Research/Science  107 upvotes 4 years ago
      Finasteride was intentionally developed to treat BPH and later approved for male pattern baldness (MPB) due to its 5AR inhibition effects. The delay in MPB approval was due to concerns about off-label use for female hirsutism and the prioritization of treating a more debilitating condition.

      community Coegin Pharma to release Follicopeptide (FOL005) by Q2 2025

      in Treatment  118 upvotes 1 year ago
      Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.

    Related Research

    1 / 1 results